ArticleCureus2024
A Pressing Emergency in Oncology: A Case Series of Patients With Posterior Reversible Encephalopathy Syndrome.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe defining characteristic of posterior reversible encephalopathy syndrome (PRES) is a reversible, predominantly vasogenic edema of the white matter, particularly affecting the parenchyma supplied by the posterior circulation. PRES is most commonly associated with hypertension. We present a case series of seven normotensive patients diagnosed with cancer who had posterior reversible encephalopathy syndrome. MATERIALS AND
methodsThis series of retrospective cases includes seven patients hospitalized between August 2022 and October 2024, all with a primary oncological condition and diagnosed with PRES either at admission or during their hospital stay. PRES was established according to the diagnostic criteria outlined in the 2012 Berlin Study. Our study concentrated on clinical characteristics, including underlying disease, triggering clinical events, chemotherapy agents, and outcome measures such as reversibility, functional status, and mortality.
resultsThe median age of patients in this study was 48 years. No patient exhibited significantly elevated blood pressure during their inpatient stay. Altered consciousness with seizures was the primary initial manifestation in most patients, followed by headache. The predominant observation on the MRI was T2 flair hyperintensity in the posterior circulation. All subjects attained nearly full neurological recovery by 28 days, regardless of steroid therapy. The 90-day all-cause mortality rate was 14% (one out of seven patients). There were no fatalities attributable to PRES.
conclusionPosterior reversible encephalopathy syndrome is a neurological emergency that may evade the discerning attention of the attending physician. Owing to the extensive range of clinical features and MRI findings, the list of differential diagnoses is substantial. The reversibility of symptoms, while not always applicable, is predominantly certain, as demonstrated in our case series. We must extend our focus beyond conventional risk variables such as hypertension to consider additional clinical insults. Delayed diagnosis may lead to worse neurological outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.